CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia

被引：0
作者：
Na Yang
Caili Zhang
Yingchun Zhang
Yuting Fan
Jing Zhang
Xiaojin Lin
Ting Guo
Yangzuo Gu
Jieheng Wu
Jianmei Gao
Xing Zhao
Zhixu He
机构：
[1] Guizhou Medical University (GMU),Tissue Engineering and Stem Cell Experiment Center
[2] Guizhou Medical University,Department of Immunology, College of Basic Medical Sciences
[3] Guizhou Medical University,Department of Biology, School of Basic Medical Sciences
[4] the Affiliated Hospital of Guizhou Medical University,Department of Gynecology
[5] Sichuan University,State Key Laboratory of Biotherapy and Cancer Center
[6] Zunyi Medical University,School of Pharmacy
[7] Chinese Academy of Medical Sciences),Key Laboratory of Adult Stem Cell Translational Research
[8] the Affiliated Hospital of Zunyi Medical University,Department of Pediatrics
来源：
Journal of Translational Medicine | / 22卷
关键词：
Chimeric antigen receptor; Natural killer cells; Dual targets; mRNA; Acute lymphoblastic leukemia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 45 条
  • [41] CD19 CAR-Targeted T Cells Induce Long-Term Remission and B Cell Aplasia in an Immunocompetent Mouse Model of B Cell Acute Lymphoblastic Leukemia
    Davila, Marco L.
    Kloss, Christopher C.
    Gunset, Gertrude
    Sadelain, Michel
    PLOS ONE, 2013, 8 (04):
  • [42] Dual T cell receptor/chimeric antigen receptor engineered NK-92 cells targeting the HPV16 E6 oncoprotein and the tumor-associated antigen L1CAM exhibit enhanced cytotoxicity and specificity against tumor cells
    Quiros-Fernandez, Isaac
    Liborio-Ramos, Sofia
    Leifert, Lena
    Schoenfelder, Bruno
    Vlodavsky, Israel
    Cid-Arregui, Angel
    JOURNAL OF MEDICAL VIROLOGY, 2024, 96 (05)
  • [43] Case report: Deep molecular remissions post two separate CD19-targeted chimeric antigen receptor T-cell therapies do not prevent disease from relapsing in Philadelphia chromosome-positive acute lymphoblastic leukemia
    Tang, Yu
    Fei, Xiaoming
    Yu, Xianqiu
    Cao, Jiang
    Wang, Lixia
    Lei, Fang
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [44] Real World Experience of Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cells Targeting CD19 in Patients with Acute Lymphoblastic Leukemia (ALL) and Diffuse Large B-Cell Lymphoma (DLBCL) Using the Center for International Blood and Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry
    Pasquini, Marcelo
    Hu, Zhen-Huan
    Zhang, Yiyun
    Grupp, Stephan
    Hematti, Peiman
    Jaglowski, Samantha
    Keating, Amy
    Nikiforow, Sarah
    Philips, Christine
    Pulsipher, Michael
    Shah, Sweta
    Steinert, Patricia
    Yanik, Gregory
    Wang, Hailin
    Horowitz, Mary
    Bleikardt, Eric
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S267 - S267
  • [45] KTE-C19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL): Outcomes in Patients Who Were Treated with Prior Blinatumomab in ZUMA-3
    Shah, Bijal D.
    Oluwole, Olalekan O.
    Baer, Maria R.
    Bishop, Michael R.
    Holmes, Houston
    Schiller, Gary J.
    Donnellan, William
    O'Dwyer, Kristen M.
    Mardiros, Armen
    Rossi, John M.
    Shen, Tong
    Xue, Allen
    Jain, Rajul K.
    Vezan, Remus
    Wierda, William G.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S184 - S184
12345